| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8656633 | Atherosclerosis | 2018 | 9 Pages |
Abstract
Plasma LCAT mass concentration is upregulated in CAD patients and inversely related to plaque volume, suggesting atheroprotective effects. LCAT mass concentration outperformed LCAT activity in risk prediction models for atheroma burden, suggesting that LCAT mass is a key variable in atheroprotection. Further studies assessing LCAT as a therapeutic target in cardiovascular disease are warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Catherine Gebhard, David Rhainds, Gang He, Josep Rodés-Cabau, Shahar Lavi, J. David Spence, Lawrence Title, Simon Kouz, Philippe L. L'Allier, Jean Grégoire, Reda Ibrahim, Mariève Cossette, Marie-Claude Guertin, Robert Beanlands, Eric Rhéaume,